Over the past three years, the RNA Readiness + Response (R3) program has united leading academics, technologists, and researchers to pioneer the continuous production of high-quality RNA – advancing treatments for conditions ranging from cancer to Zika. Based on the significant advances in the program, Wellcome Leap, CEPI, and their partners are now ready to scale this breakthrough globally. With a worldwide network of biofoundries, we aim to accelerate the production of next-generation medicines and simultaneously ensure an economically sustainable, on-demand capacity to respond rapidly to future pandemics.